Our hypothesis is that if peptide-based p53 molecules had longer half-lives and could induce multiple pathways for apoptosis (e.g., through transactivation of p53 target genes for intrinsic and extrinsic pathways), they could have greater potential utility as therapeutic agents for mutant p53 cancers. This evidence concerns the gene TP53 and cancer.